Notable Upgrades: CyberArk Software (CYBR), Capnia (CAPN), Facebook (FB), Dynavax (DVAX), NephroGenex (NRX)

Bank of America (BAC) initiated coverage of CyberArk Software, Ltd. (CYBR) with a ‘Buy’ rating and a $60 price target, which represents expected upside of 15.40% to the stock’s current price of $52.40. From a sentiment standpoint, most analysts seem to be in the hold camp, as the name boasts 2 ‘Buys’, compared to 5 ‘Holds’ and 2 ‘Sell’.

On valuation measures, CyberArk shares are currently priced at 156.42x this year’s forecasted earnings compared to the industry’s 37.14x earnings multiple. Ticker has a PEG and forward P/E ratio of 32.19 and 134.10, respectively. Price/Sales for the same period is 13.98 while EPS is $0.34.

In the past 52 weeks, shares of the Sunnyvale, California-based company have traded between a low of $22.12 and a high of $70.48 and are now at $52.40. Shares are up 74.47% year-over-year and 22.80% year-to-date. CYBR has a median Wall Street price target of $49.00 with a high target of $55.00.

In a report published Monday, Maxim Group analysts initiated coverage on Capnia, Inc. (CAPN) with a ‘Buy’ rating and $9.00 price target.

The name is currently printing a higher than average trading volume with the issue trading more than 1.6 million shares, compared to the average volume of 572K. The stock began trading this morning at $6.08 to currently trade 27% higher from the prior days close of $5.37. On an intraday basis it has gotten as low as $6.05 and as high as $7.12.

Capnia shares have declined 8.67% in the last 4 weeks and advanced 223.49% in the past three months. Over the past 5 trading sessions the stock has lost 15.57%. Shares of Redwood City, Calif.-based therapeutics products developer are up 260.40% this year.

Facebook, Inc. (FB) was reiterated an ‘Overweight’ by Piper Jaffray analysts on Monday. The broker also raised its price target on the stock to $92 from $84, implying 9.50% expected return.

Facebook, Inc., currently valued at $234.78 billion, has a median Wall Street price target of $91.00 with a high target of $107.00. Approximately 5.8 million shares have already changed hands, compared to the stock’s average daily volume of 24.92 million.

In the past 52 weeks, shares of the social networking company have traded between a low of $54.66 and a high of $84.60 with the 50-day MA and 200-day MA located at $78.17 and $77.05 levels, respectively. Additionally, shares of FB trade at a P/E ratio of 1.39 and have a Relative Strength Index (RSI) and MACD indicator of 67.55 and +3.27, respectively.

FB currently prints a one year return of 25.13% and a year-to-date return of around 7.50%.

Analysts at JP Morgan (JPM) are out with a report this morning upgrading shares of Dynavax Technologies Corporation (DVAX) with an ‘Overweight‘ from ‘Neutral‘ rating. The firm raised its price target for the company to $36 from $15, implying 140% upside to the name’s new price target.

Dynavax Technologies Corp. shares have a t-12 price-to-sales ratio of 59.29. EPS for the same period is ($3.45).

In the past 52 weeks, shares of Berkeley California-based clinical-stage biopharmaceutical company have traded between a low of $12.50 and a high of $24.61 and are now at $24.31. Shares are up 20.32% year-over-year and 34.16% year-to-date.

Shares of pharmaceutical company NephroGenex, Inc. (NRX) are up 57 cents, or 7.69%, at $7.98, after MLV & Co. analysts today initiated coverage of the firm, giving NephroGenex a ‘Buy’ rating, and price targets of $20.

NRX, currently valued at $70.71 million, has a high Wall Street price target of $15.00. Approximately 52K shares have already changed hands, compared to the stock’s average daily volume of 553K.

In the past 52 weeks, shares of the clinical-stage biopharmaceutical company have traded between a low of $3.96 and a high of $17.98. The name currently prints a one year loss of about 23% and a year-to-date loss of around 44.50%.

Be the first to comment

Leave a Reply

Your email address will not be published.


*